Medtronic (MDT) is reportedly looking at adjusting its global manufacturing footprint amid heightened concerns that the U.S.

Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

In a welcome move, Medtronic stock saw its Relative Strength Rating improve from 67 to 73 on Tuesday. Please watch the video ...

Medtronic's agnostic approach to global challenges, including tariffs and AI, ensures success and innovation in healthcare ...

The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...